secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001558370-24-012293
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path posts Q2 2024 net loss of $1.9M; cash position improves to $4.0M
-------------------------------------------------------------------------

- Net loss of $1.9M ($1.16 per share) vs $4.2M ($10.64 per share) in Q2 2023.
- Cash $4.0M at June 30, 2024, up from $1.1M at Dec 31, 2023; operating cash burn $4.3M.
- Closed $4.0M private placement in June: 1.8M shares + warrants at $2.21/share.
- R&D expense down to $1.9M from $3.1M; G&A flat at $1.2M.
- Presented interim Phase 2 data for prexigebersen in AML at ASCO and EHA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024012293/0001558370-24-012293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024012293/bpth-20240815x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer